"CAR T Cells Could Provide Curative Strategies In Myeloma" - Brandon Scalea
Encouraging clinical trial findings have demonstrated that chimeric antigen receptor (CAR) T-cell therapy has promise for patients with relapsed/refractory multiple myeloma; however, more data are needed to decide the best placement of this therapy, said Deepu Madduri, MD, assistant professor of medicine, hematology and medical oncology at the Icahn School of Medicine at Mount Sinai. “The biggest challenge we have with this therapy is slot limitation.” She added, “Recently, with the introduction of monoclonal antibodies, we are using quadruplet regimens in some cases. We can actually do lenalidomide (Revlimid), bortezomib (Velcade), and dexamethasone (VRD), plus daratumumab (Darzalex). These are in clinical trials right now.”
- Deepu Madduri, MD, Assistant Professor, Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai